Drug intelligence / Profile preview

SK3530 + tamsulosin

Development stage: Unknown
Lead developer: SK Chemicals
Modality: Small Molecules
Administration: Oral

Overview

**SK3530 + tamsulosin** is a combination drug consisting of the compound SK3530 and tamsulosin. Tamsulosin is a well-characterized alpha-1A adrenergic receptor antagonist, primarily used to relax smooth muscle in the prostate and bladder neck to improve urinary flow in conditions such as benign prostatic hyperplasia (BPH). No specific pharmaceutical or clinical information is publicly available for the compound SK3530, and it is not a recognized or widely characterized agent in scientific literature or regulatory databases. Unless SK3530 refers to an unpublished or investigational compound with unknown pharmacology, mechanistic and developmental details for this combination cannot be determined.

Other names: SK3530 + tamsulosin

Targets

ADRA1A (α1A)ADRA1B (α1B)PDE5 (Phosphodiesterase 5A)

Beyond the preview

Go deeper on SK3530 + tamsulosin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SK3530 + tamsulosin.

Explore the full profile